Chemomab Therapeutics (CMMB) Interest Coverage Ratio (2018 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Interest Coverage Ratio came in at 6.93 in Q4 2023, up 66.6% on a YoY basis from 4.16 in Q4 2022, and up 59.02% quarter-over-quarter from 16.9 in Q3 2023.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Interest Coverage Ratio (2018 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has reported Interest Coverage Ratio for 4 consecutive years, with 6.93 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Interest Coverage Ratio rose 66.6% year-over-year to 6.93; the trailing twelve-month figure through Dec 2023 stood at 17.91 (down 2210.99% YoY), and the FY2023 full-year result was 18.56, up 76.45% from the prior year.
- Interest Coverage Ratio advanced to 6.93 in Q4 2023 per CMMB's latest filing, from 16.9 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 246.83 in Q2 2019 and bottomed at 33.09 in Q3 2022.
- Historically, Interest Coverage Ratio has averaged 17.36 across 3 years, with a median of 6.93 in 2023.
- The sharpest annual moves came in 2019 and 2023: Interest Coverage Ratio soared 4680.1% in 2019, then sank 297.22% in 2023.
- Over 3 years, Interest Coverage Ratio stood at 1.4 in 2019, then plunged by 1579.08% to 20.74 in 2022, then surged by 66.6% to 6.93 in 2023.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 6.93, 16.9, and 29.64 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.08 |
| 10 | Chemomab Therapeutics | 19.49 Mn | 19.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -6.93 |
| Sep 30, 2023 | -16.90 |
| Jun 30, 2023 | -29.64 |
| Dec 31, 2022 | -20.74 |
| Sep 30, 2022 | -33.09 |
| Jun 30, 2022 | 15.03 |
| Dec 31, 2019 | 1.40 |
| Sep 30, 2019 | 0.31 |
| Jun 30, 2019 | 246.83 |
| Dec 31, 2018 | -14.04 |
| Sep 30, 2018 | 34.79 |
| Jun 30, 2018 | 5.16 |